Riskpilot← Back to searchSign inGet full accessWautor Laboratories AB
ABActiveOrg 5590601679Flo Bergskullen 1 BOther non-specialised retail sale · NACE 4712Est. 20160 employees
Revenue 2024
SEK 2,4M
-19% vs 2023
EBITDA margin
2.0%
+108% vs 2023
Equity ratio
81.6%
Financial strength
Net profit 2024
SEK 133K
+203% vs 2023
| Revenue | SEK 2,4M | -19% |
| EBITDA | SEK 49K | +108% |
| Net profit | SEK 133K | +203% |
| Total assets | SEK 1,8M | +1% |
| Equity | SEK 1,5M | +10% |
| Employees | 0 | — |
Legal name
Wautor Laboratories AB
Org number
5590601679
Legal form
Aktiebolag
NACE code
4712 · Other non-specialised retail sale
Founded
22 april 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten externa firmatecknaren
Company purpose
Bolaget skall bedriva försäljning av hälsokostprodukter samt hygienprodukter och därmed förenlig verksamhet.
Address
Flo Bergskullen 1 B
Email
elisabet@levenskog.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 313 | 4 410 | 3 454 | 2 999 | 2 421 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 958 | −12 | −39 | −595 | 49 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 958 | −12 | −39 | −595 | 49 |
| Net financials | −5 | −9 | 33 | 96 | 93 |
| Profit before tax | 718 | 7 | 95 | −129 | 142 |
| Tax | −154 | −3 | −22 | −0 | −9 |
| Net profit | 564 | 4 | 73 | −129 | 133 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 552 | 3 101 | 2 732 | 1 794 | 1 805 |
| Equity | 1 390 | 1 394 | 1 467 | 1 339 | 1 472 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 663 | 1 236 | 894 | 456 | 333 |
| Total debt | 1 663 | 1 236 | 894 | 456 | 333 |
EBITDA margin
2.0%
This company
15.8%
Market median
-87% vs market
20202024
Equity ratio
81.6%
This company
38.2%
Market median
+114% vs market
20202024
Return on equity
9.0%
This company
18.4%
Market median
-51% vs market
20202024
Net profit margin
5.5%
This company
8.1%
Market median
-32% vs market
20202024
Asset turnover
1.34×
This company
1.12×
Market median
+20% vs market
20202024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EB External Signatory | External Signatory | 2022 |
| Former (1) | ||
BM | Audit | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Wautor Laboratories AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Martin Niklas Karlsson | Audit | 0 companies |
| Elisabet Birgit Levenskog | External Signatory | 0 companies |
| Tor Wauer | Deputy Board Member | 0 companies |
| Dennis Wauer | Board of Directors | 0 companies |